Lexeo Therapeutics Inc. (LXEO)
LXEO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.74
-9.87% on the day
Market cap
$224.8M
Micro cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LXEO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001907108 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
No annual revenue filed since the period ending 2022-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-11-26 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 359 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PLX | Protalix BioTherapeutics Inc. (DE) | $2.75 | -1.08% | $221.6M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
| FATE | Fate Therapeutics Inc. | $2.00 | -6.10% | $239.6M |
| ALEC | Alector Inc. | $1.87 | -10.10% | $208.8M |
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
| IKT | Inhibikase Therapeutics Inc. | $1.76 | -4.61% | $245.6M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier